A carregar...
Targeting MOR-mGluR(5) heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5
Pain is among the most common symptoms in cancer and approximately 90% of patients experience end-stage cancer pain. The management of cancer pain is challenging due to the significant side effects associated with opioids, and novel therapeutic approaches are needed. MMG22 is a bivalent ligand conta...
Na minha lista:
| Publicado no: | Neuropharmacology |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210724/ https://ncbi.nlm.nih.gov/pubmed/31271770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2019.107690 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|